托瑞米芬联合戈舍瑞林治疗受体阳性绝经前乳腺癌的疗效评估

Evaluation on curative eEffect of toremifene combined with goserelin in the treatment of receptor positive recipient-positive premenopausal breast cancer

目的研究托瑞米芬联合戈舍瑞林治疗受体阳性绝经前乳腺癌的临床疗效。方法随机抽取我院于2016年2月～2017年12月收治的110例受体阳性绝经前乳腺癌患者,采用随机综合序贯法分为参照组和治疗组各55例。参照组采用托瑞米芬治疗,治疗组则采用托瑞米芬联合戈舍瑞林治疗。观察记录两组患者采用药物治疗的总有效率、术后6、12、18、24、30月生存率及不良反应发生率,并采用生活质量及生活活动能力评分对患者生活状态进行评定,后对比分析。结果 (1)治疗组治疗总有效率(94.55%),参照组治疗总有效率(72.73%),差异有统计学意义(P <0.05);(2)两组术后6、12月生存率差异无统计学意义(P> 0.05)。治疗组18、24、30月生存率与参照组相比明显要高,表明2组近期疗效相等,但治疗组远期疗效相对显著,差异有统计学意义(P <0.05);(3)治疗组不良反应发生率(7.27%),参照组不良反应发生率(29.09%),差异有统计学意义(P <0.05);(4)评分结果显示,治疗组生存质量评分及生活活动能力评分与参照组相比明显要高,差异有统计学意义(P <0.05)。结论托瑞米芬联合戈舍瑞林治疗受体阳性绝经前乳腺癌患者具有显著效果,其远期疗效显著,并有效减少不良反应对患者造成的影响,安全性及可行性较高,值得应用于临床推广。

Objective To study the clinical curative effect of toremifene combined with goserelin in the treatment of receptor positive recipient-positive postmenopausal breast cancer.Methods One hundred and ten patients with receptor positive recipient-positive postmenopausal breast cancer who were admitted to our hospital from February 2016 to December 2017 were randomly selected.They were divided into the reference group and the treatment group according to random synthesis sequential method,with 55 cases in each group.The reference group was treated with toremifene while the treatment group was treated with toremifene combined with goserelin.The total effective rate of drug treatment,the survival rate of 6 months,12 months,18 months,24 months,and 30 months after surgery and the incidence of adverse reactions were observed and recorded.The quality of life and life activity ability scores were used to assess the living conditions of patients.Then they were compared and analyzed.Results(1)The total effective rate of treatment in the treatment group and the reference group were respectively 94.55%and 72.73,with statistical significance(P<0.05).(2)The survival of 6 months and 12 months after surgery in 2 groups had no significant difference and there was no statistical significance(P>0.05).The survival rate of 18,24,and 30 months after surgery in the treatment group was significantly higher than that of the reference group,indicating that the short-term effects of the two groups were equal,but the long-term effect of the treatment group was relatively significant.There was statistical significance(P<0.05).(3)The incidence of adverse reactions in the treatment group was 7.27%and that in the reference group was 29.09%.There was statistical significance(P<0.05).(4)The scores showed that the quality of life score and life activity ability score of the treatment group were significantly higher than those of the reference group,which were statistically significant(P<0.05).Conclusion Toremifene combined with goserelin in the treatment of receptor positive recipient-positive postmenopausal breast cancer has significant effects and its long-term effect is significant.It can effectively reduce the effect of adverse reactions on patients and it has high safety and feasibility,which is worthy of clinical promotionand application.